Medication type Tirzepatide appears to preserve slightly more lean mass than semaglutide based on trial data (26% vs 40% of weight lost as lean mass), although the trials werent directly comparable 1,2
Among participants, background use of GLP-1RA and SGLT2i was 5.8% and 8.9%, respectively, and treatment effect of finerenone on cardiovascular death was consistent regardless of those medication usages
This matters because systolic blood pressure is the top number in a blood pressure reading
Acknowledgements We acknowledge the scientists whose discoveries were the basis for this review, thank the anonymous peer-reviewers for helpful comments, and apologize to our colleagues whose work we could not cite
Some GLP-1 users report insomnia on semaglutide or sleep disruption on tirzepatide , which creates a vicious cycle: the medication disrupts sleep, poor sleep promotes a stall, and the stall causes frustration that further impairs sleep quality